(Solid Tumors) Is Keytruda Effective?
(Solid Tumors) Is Keytruda Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
(Solid Tumors) Is Keytruda Effective?
- February 3, 2023
- Read time: 1 minute
On January 9, 2023, Kaysia Ludford and colleagues from The University of Texas MD Anderson Cancer Center published results of a Phase 2 clinical trial (NCT04082572) in the Journal of Clinical Oncology, evaluating the efficacy and safety of Keytruda as neoadjuvant therapy in patients with advanced metastatic solid tumors with MSI-High and dMMR status.
This Phase 2 clinical trial was conducted as an open-label trial at independent facilities, administering Keytruda (600mg per 3-week cycle, maximum 6 months treatment duration) as neoadjuvant therapy to patients with advanced metastatic solid tumors with MSI-High and dMMR status. Following surgery, patients continued treatment for up to one year based on individual choice. The primary endpoints were pathologic complete response rate and safety, while secondary endpoints included organ preservation rate in patients not undergoing surgery.
Results from 35 enrolled patients (27 with colorectal cancer, 8 with non-colorectal cancer) were as follows: among 33 patients evaluable for efficacy, the objective response rate was 82%, and the primary endpoint of pathologic complete response rate (in 17 patients who underwent surgery) was 65%.
Regarding safety, no new adverse events were identified in this trial, consistent with the current safety profile of Keytruda from other clinical trials.
Based on Phase 2 clinical trial results, Kaysia Ludford and colleagues concluded: Patients with advanced metastatic solid tumors with MSI-High and dMMR status treated with Keytruda as neoadjuvant therapy demonstrated good tolerability to adverse events and favorable pathologic complete response rates, offering patients an organ-preservation option.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.22.01351?journalCode=jco
-
Clinical Trial Medications
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase 2 Trial Results. (Lung Cancer) HER2-Mutated Non-Small Cell Lung Cancer with Enhertu Effective? (Lung Cancer) Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4